Professor, Medicine, University of California Los Angeles David Geffen SOM
Hematology
Dr. Lee S. Rosen, MD
|
|
Give Review
Rosen practices Hematology. He researched medicine at Baylor College of Medicine. He over the years received 2 awards: "Fellow (FACP)" and "Super Doctor". Rosen has written publications. He has 51 publications published with PubMed. The lastest publication is: 'Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.' Rosen accepts Medicare payments and is listed with Medicare.gov.
Publications
- Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
- Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
- Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors.
- Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib.
- An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer.
- Phase 1 Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors.
- A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
- Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.
- A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
- Endoglin for targeted cancer treatment.
- A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas.
- Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors.
- Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
- A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer.
- A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors.
- Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors.
- Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
- Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors.
- A Phase I Dose Esclation Study of Tivantinib (ARQ 197) in Adult Pts w Metastatic Solid Tumors.
- Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
- Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma.
- Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.
- Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
- Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
- Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
- New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference.
- Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
- Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
- Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.
- Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
- Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note.
- VEGF-targeted therapy: therapeutic potential and recent advances.
- Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
- Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a random...
- Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies.
- New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
- Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
- Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myelo...
- Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial...
- Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.
- Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.
- Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
- Inhibitors of the vascular endothelial growth factor receptor.
- Biologic approaches to the treatment of gastrointestinal malignancy.
- Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
- Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Schools
Baylor Coll Of Med
University Of California Los Angeles
Procedures Preformed
- Thoracentesis
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Awards
- Fellow (FACP)
- Super Doctor
Education
-
UCLA Medical Center -
Baylor College of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Daniel J. Lieber, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rena D. Callahan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Omid Hamid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew E. Hendifar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert A. Eradat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silvana Martino, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan W. Goldman, MD |
|
|
Dr. Leonard S. Goldberg, MD |
|
|
Dr. Thompson Adams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arun S. Singh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Timmerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Doris V. Quon, MD |